Literature DB >> 12213590

Transcriptional regulators of the human multidrug resistance 1 gene: recent views.

Stéphane Labialle1, Landry Gayet, Eric Marthinet, Dominique Rigal, Loris G Baggetto.   

Abstract

The multidrug resistance (MDR) phenotype is the major cause of failure of cancer chemotherapy. This phenotype is mainly due to the overexpression of the human MDR1 (hMDR1) gene. Several studies have shown that transcriptional regulation of this gene is unexpectedly complex and is far from being completely understood. Current work is aimed mainly at defining unclear and new control regions in the hMDR1 gene promoter as well as clarifying corresponding signaling pathways. Such studies provide new insights into the mechanisms by which xenobiotic molecules might modify the physiological hMDR1 expression as well as the possible role of oncogenes in the pathological dysregulation of the gene. Here we report recent findings on the regulation of hMDR1 which may help define specific targets aimed at modulating its transcription.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12213590     DOI: 10.1016/s0006-2952(02)01156-5

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  44 in total

1.  Identifying candidate causal variants responsible for altered activity of the ABCB1 multidrug resistance gene.

Authors:  Nicole Soranzo; Gianpiero L Cavalleri; Michael E Weale; Nicholas W Wood; Chantal Depondt; Richard Marguerie; Sanjay M Sisodiya; David B Goldstein
Journal:  Genome Res       Date:  2004-06-14       Impact factor: 9.043

Review 2.  Oncolytic virus as a cancer stem cell killer: progress and challenges.

Authors:  Jingzhen Ding
Journal:  Stem Cell Investig       Date:  2014-12-28

3.  Cardamonin, a natural chalcone, reduces 5-fluorouracil resistance of gastric cancer cells through targeting Wnt/β-catenin signal pathway.

Authors:  Gaochao Hou; Xiang Yuan; Yi Li; Gaoyu Hou; Xianli Liu
Journal:  Invest New Drugs       Date:  2019-05-17       Impact factor: 3.850

4.  Effects of budesonide on P-glycoprotein expression in intestinal cell lines.

Authors:  A Maier; C Zimmermann; C Beglinger; J Drewe; H Gutmann
Journal:  Br J Pharmacol       Date:  2006-12-18       Impact factor: 8.739

Review 5.  Modulation of P-glycoprotein at the blood-brain barrier: opportunities to improve central nervous system pharmacotherapy.

Authors:  David S Miller; Björn Bauer; Anika M S Hartz
Journal:  Pharmacol Rev       Date:  2008-06-17       Impact factor: 25.468

6.  Casein Kinase 2 (CK2)-mediated Phosphorylation of Hsp90β as a Novel Mechanism of Rifampin-induced MDR1 Expression.

Authors:  So Won Kim; Md Hasanuzzaman; Munju Cho; Ye Rang Heo; Min-Jung Ryu; Na-Young Ha; Hyun June Park; Hyung-Yeon Park; Jae-Gook Shin
Journal:  J Biol Chem       Date:  2015-05-20       Impact factor: 5.157

7.  Targeted Cancer Therapy with Tumor Necrosis Factor-Alpha.

Authors:  Weibo Cai; Zachary J Kerner; Hao Hong; Jiangtao Sun
Journal:  Biochem Insights       Date:  2008-07-22

8.  Sestamibi is a substrate for MDR1 and MDR2 P-glycoprotein genes.

Authors:  Brigid Joseph; Kuldeep K Bhargava; Harmeet Malhi; Michael L Schilsky; Diwakar Jain; Christopher J Palestro; Sanjeev Gupta
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-01-21       Impact factor: 9.236

Review 9.  The multifaceted NF-kB: are there still prospects of its inhibition for clinical intervention in pediatric central nervous system tumors?

Authors:  Mariana Medeiros; Marina Ferreira Candido; Elvis Terci Valera; María Sol Brassesco
Journal:  Cell Mol Life Sci       Date:  2021-07-31       Impact factor: 9.261

10.  New invMED1 element cis-activates human multidrug-related MDR1 and MVP genes, involving the LRP130 protein.

Authors:  Stéphane Labialle; Guila Dayan; Landry Gayet; Dominique Rigal; Joël Gambrelle; Loris G Baggetto
Journal:  Nucleic Acids Res       Date:  2004-07-22       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.